MedTrace Logo

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

NCT05189444 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 672

Last updated 2022-03-22

No results posted yet for this study

Summary

The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. The aim of this prospective study is to investigate the efficacy of Triple Therapy with Vonoprazan, Amoxicillin, and Bismuth for eradication of Hp, compared with standard quadruple therapy.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Vonoprazan

20mg bid

DRUG

Amoxicillin

0.75g tid

DRUG

Esomeprazole

20mg bid

DRUG

Amoxicillin

1.0g bid

DRUG

Clarithromycin

0.5g bid

DRUG

Bismuth potassium citrate

0.22g bid

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Bin Cheng, Doctor · Tongji Hospital

  • si xiong, Doctor · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-25
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05189444 on ClinicalTrials.gov